Dr. Melissa Johnson on Lung Cancer Research to Watch
By Rob Dillard - Last Updated: November 13, 2023Lung Cancers Today spoke with Melissa Johnson, MD, program director of lung cancer research at the Sarah Cannon Research Institute. Dr. Johnson discussed ongoing lung cancer trials she’s interested in, challenges and unmet needs in lung cancer trials and treatments, exciting lung cancer findings presented at the European Society for Medical Oncology Congress 2023, and more.
Advertisement
Advertisement
Related Posts
Certain surgical procedures and margins were more frequent in patients who had suture-line recurrences.
The long-term follow-up data shows that PFS remains unreached in the subgroup of Asian patients in the CROWN study.
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.